In the all-important Hospitals segment, Revenue in JH2017 was up...

In the all-important Hospitals segment, Revenue in JH2017 was up 3.8% on pcp, but operating EBITDA was flat on JH2016.

I suspect the market will not be overly enamored with that outcome.

Valuations of 20x P/E and 12x EV/EBITDA probably require something more than static financial performance.

I have been wanting to buy HSO for some time, as I think it has some attractive long-term fundamentals.
But I've always thought it to be somewhat over-valued.

Looks like I might get my opportunity in the days/weeks ahead.